CTM suppresses cancer cell growth in vitro and in vivo more efficiently in cells expressing p53R175H with upregulation of MDM2, p21, and PUMA than those expressing wild-type p53 and p53R273H, as well as null for p53 (37). The gene discussed is TP53; the disease is cancer.